# Michael B. Andrews

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-b-andrews/

## Facts

| Field | Value |
| --- | --- |
| Citations | 116 |
| Field | Gastrointestinal motility and disorders |
| h-index | 3 |
| i10-index | 2 |
| Last Known Institution | Virginia Commonwealth University |
| OpenAlex ID | https://openalex.org/A5088164827 |
| ORCID iD | 0000-0002-2969-4769 |
| Works | 16 |

## Researcher papers

- [Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer.](https://scholariq.org/papers/mitoxantrone-fluorouracil-and-high-dose-leucovorin-an-effective-well-tolerated/)
- [Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin’s Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network](https://scholariq.org/papers/rituximab-plus-short-duration-chemotherapy-as-first-line-treatment-for/)
- [Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) database](https://scholariq.org/papers/gastroparesis-treatment-options-metoclopramide-and-prucalopride-analysis-of-the/)
- [Safety of the contrast enhancement agent sulfur hexafluoride in ultrasound: Analysis of the Federal Drug Administration Adverse Event Reporting System database](https://scholariq.org/papers/safety-of-the-contrast-enhancement-agent-sulfur-hexafluoride-in-ultrasound/)
- [Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications](https://scholariq.org/papers/comprehensive-analysis-of-adverse-drug-reactions-associated-with-teduglutide/)
- [Thyrotoxicosis-Induced Myopathic Dysphagia Treated With Plasmapheresis](https://scholariq.org/papers/thyrotoxicosis-induced-myopathic-dysphagia-treated-with-plasmapheresis/)
- [Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database](https://scholariq.org/papers/diarrhea-predominant-irritable-bowel-syndrome-treatment-options-eluxadoline/)
- [Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Following Initiation of Sulfasalazine for Ulcerative Colitis: A Yearlong Clinical Challenge](https://scholariq.org/papers/drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-syndrome-following/)
- [An analysis of safety data from the first year of resmetirom](https://scholariq.org/papers/an-analysis-of-safety-data-from-the-first-year-of-resmetirom/)
- [A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications](https://scholariq.org/papers/a-comprehensive-analysis-of-the-adverse-drug-events-of-metastatic-and/)

## Researcher topics

- [Gastrointestinal motility and disorders](https://scholariq.org/topics/gastrointestinal-motility-and-disorders/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

## Researcher university

- [Virginia Commonwealth University](https://scholariq.org/institutions/virginia-commonwealth-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.